Cargando…

Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study

Bone metastasis is common in advanced lung cancer, with the incidence reported to be 30%, and radiotherapy (RT) is used for pain relief from bone metastasis. The present study aimed to identify factors affecting local control (LC) of bone metastasis from lung cancer and to assess the significance of...

Descripción completa

Detalles Bibliográficos
Autores principales: Makita, Kenji, Hamamoto, Yasushi, Kanzaki, Hiromitsu, Nagasaki, Kei, Kozuki, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265332/
https://www.ncbi.nlm.nih.gov/pubmed/37323814
http://dx.doi.org/10.3892/ol.2023.13889
_version_ 1785058510909734912
author Makita, Kenji
Hamamoto, Yasushi
Kanzaki, Hiromitsu
Nagasaki, Kei
Kozuki, Toshiyuki
author_facet Makita, Kenji
Hamamoto, Yasushi
Kanzaki, Hiromitsu
Nagasaki, Kei
Kozuki, Toshiyuki
author_sort Makita, Kenji
collection PubMed
description Bone metastasis is common in advanced lung cancer, with the incidence reported to be 30%, and radiotherapy (RT) is used for pain relief from bone metastasis. The present study aimed to identify factors affecting local control (LC) of bone metastasis from lung cancer and to assess the significance of moderate RT dose escalation. This was a retrospective cohort study, where LC of bone metastasis from lung cancer that had received palliative RT was reviewed. LC at RT sites was evaluated with follow-up computed tomography (CT). The influence of treatment-, cancer- and patient-related risk factors for LC was assessed. A total of 317 metastatic lesions in 210 patients with lung cancer were evaluated. The median RT dose (biologically effective dose calculated using an α/β of 10 Gy; BED10) was 39.0 Gy (range, 14.4-50.7 Gy). The median follow-up time for survival and median radiographic follow-up time were 8 (range, 1–127) and 4 (range, 1–124) months, respectively. The 0.5-year overall survival and LC rates were 58.9 and 87.7%, respectively. The local recurrence rate in RT sites was 11.0%, and bone metastatic progression, except in RT sites, was observed in 46.1% at the time of local recurrence or the last follow-up CT of the RT sites. According to multivariate analysis, RT sites, pre-RT neutrophil to lymphocyte ratio (NLR), post-RT non-administration of molecular-targeting agents (MTs), and non-administration of bone modifying agents (BMAs) were significant unfavorable factors for LC of bone metastasis. Moderate RT dose escalation (BED10 >39 Gy) tended to improve the LC of RT sites. In cases without MTs, moderate dose escalation of RT dose improved the LC of RT sites. In conclusion, treatment (post-RT MTs and BMAs), cancer (RT sites) and patient (pre-RT NLR)-related risk factors had a large impact on improving the LC of RT sites. Moderate RT dose escalation seemed to have a small impact on improving the LC of RT sites.
format Online
Article
Text
id pubmed-10265332
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-102653322023-06-15 Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study Makita, Kenji Hamamoto, Yasushi Kanzaki, Hiromitsu Nagasaki, Kei Kozuki, Toshiyuki Oncol Lett Articles Bone metastasis is common in advanced lung cancer, with the incidence reported to be 30%, and radiotherapy (RT) is used for pain relief from bone metastasis. The present study aimed to identify factors affecting local control (LC) of bone metastasis from lung cancer and to assess the significance of moderate RT dose escalation. This was a retrospective cohort study, where LC of bone metastasis from lung cancer that had received palliative RT was reviewed. LC at RT sites was evaluated with follow-up computed tomography (CT). The influence of treatment-, cancer- and patient-related risk factors for LC was assessed. A total of 317 metastatic lesions in 210 patients with lung cancer were evaluated. The median RT dose (biologically effective dose calculated using an α/β of 10 Gy; BED10) was 39.0 Gy (range, 14.4-50.7 Gy). The median follow-up time for survival and median radiographic follow-up time were 8 (range, 1–127) and 4 (range, 1–124) months, respectively. The 0.5-year overall survival and LC rates were 58.9 and 87.7%, respectively. The local recurrence rate in RT sites was 11.0%, and bone metastatic progression, except in RT sites, was observed in 46.1% at the time of local recurrence or the last follow-up CT of the RT sites. According to multivariate analysis, RT sites, pre-RT neutrophil to lymphocyte ratio (NLR), post-RT non-administration of molecular-targeting agents (MTs), and non-administration of bone modifying agents (BMAs) were significant unfavorable factors for LC of bone metastasis. Moderate RT dose escalation (BED10 >39 Gy) tended to improve the LC of RT sites. In cases without MTs, moderate dose escalation of RT dose improved the LC of RT sites. In conclusion, treatment (post-RT MTs and BMAs), cancer (RT sites) and patient (pre-RT NLR)-related risk factors had a large impact on improving the LC of RT sites. Moderate RT dose escalation seemed to have a small impact on improving the LC of RT sites. D.A. Spandidos 2023-05-31 /pmc/articles/PMC10265332/ /pubmed/37323814 http://dx.doi.org/10.3892/ol.2023.13889 Text en Copyright: © Makita et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Makita, Kenji
Hamamoto, Yasushi
Kanzaki, Hiromitsu
Nagasaki, Kei
Kozuki, Toshiyuki
Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study
title Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study
title_full Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study
title_fullStr Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study
title_full_unstemmed Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study
title_short Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study
title_sort local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: an observational retrospective cohort study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265332/
https://www.ncbi.nlm.nih.gov/pubmed/37323814
http://dx.doi.org/10.3892/ol.2023.13889
work_keys_str_mv AT makitakenji localcontrolofbonemetastasistreatedwithpalliativeradiotherapyinpatientswithlungcanceranobservationalretrospectivecohortstudy
AT hamamotoyasushi localcontrolofbonemetastasistreatedwithpalliativeradiotherapyinpatientswithlungcanceranobservationalretrospectivecohortstudy
AT kanzakihiromitsu localcontrolofbonemetastasistreatedwithpalliativeradiotherapyinpatientswithlungcanceranobservationalretrospectivecohortstudy
AT nagasakikei localcontrolofbonemetastasistreatedwithpalliativeradiotherapyinpatientswithlungcanceranobservationalretrospectivecohortstudy
AT kozukitoshiyuki localcontrolofbonemetastasistreatedwithpalliativeradiotherapyinpatientswithlungcanceranobservationalretrospectivecohortstudy